RxDoctor Payments Data

Nimish Dharia, MD

Cardiovascular Disease · New Hyde Park, NYNPI 1568484061

Payments from drug & device makers

$1,994in general payments, 2019–2025

Across 77 payments — averaging $25.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$272
  • Novo Nordisk$270
  • Boehringer Ingelheim$224
  • Boston Scientific$171
  • Abbott$152
  • Pfizer$127
  • plus $778 from 13 others

What the payments were for

  • Food & beverage$1,85993%
  • Education$1357%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,994 in reported general payments places this provider in the 50th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$1,494,970
Medicare patients
551
Services billed
7,726

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban142$215,979
EntrestoSacubitril/Valsartan41$60,191
OzempicSemaglutide21$41,510
JardianceEmpagliflozin30$38,343
XareltoRivaroxaban33$37,154
JanuviaSitagliptin Phosphate25$32,113
Repatha SureclickEvolocumab21$23,898
JanumetSitagliptin Phos/Metformin Hcl14$20,347
FarxigaDapagliflozin Propanediol12$19,111
LinzessLinaclotide13$6,916
Atorvastatin Calcium433$4,328
Metoprolol Succinate287$4,072
Metformin Hcl122$3,547
Rosuvastatin Calcium171$3,340
Amlodipine Besylate413$2,562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$127$215,979142 claims
NovartisEntresto$126$60,19141 claims
MerckJanuvia, Janumet$90$52,46039 claims
Novo NordiskOzempic$270$41,51021 claims
Boehringer IngelheimJardiance$224$38,34330 claims
Johnson & JohnsonXarelto$74$37,15433 claims
AstraZenecaFarxiga$11$19,11112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →